In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...
Read MoreHER2 status-Negative Posts on Medivizor
Evaluating ribociclib plus hormonal therapy in breast cancer
In a nutshell This study wanted to find out how well patients with hormone-receptor-positive breast cancer survived when treated with ribociclib (Kisqali) added to endocrine therapy. The study found that patients treated with this treatment combination had longer survival compared to endocrine therapy alone. Some background Advanced breast cancer can...
Read MoreLooking for patients with advanced triple negative breast cancer to test a new drug
In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced breast cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...
Read MoreSearching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor
In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreSearching for patients with triple negative breast cancer to test durvalumab and olaparib
In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...
Read MoreEvaluating carboplatin plus chemotherapy for patients with TNBC
In a nutshell This study evaluated whether adding carboplatin (Paraplatin) to chemotherapy improved survival for patients with triple-negative breast cancer (TNBC). This study found that this treatment combination improved long-term survival without tumor growth or spread in these patients. Some background TNBC is a type...
Read MoreSearching for patients with triple negative breast cancer to test this new treatment combination
In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read MoreLooking for patients with estrogen receptor-positive breast cancer to test a new treatment combination
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read MoreSearching for patients with triple negative breast cancer to test a new medication
In a nutshell This phase 3 trial will investigate the safety and effectiveness of adagloxad simolenin (AGS)/OBI-821 in triple-negative breast cancer (TNBC). The main outcome will be a change in survival without invasive disease. The details Breast cancer (BC) is one of the most common cancers. BC treatment depends on the tumor type....
Read MoreLooking for patients with early-stage breast cancer to test a combination treatment
In a nutshell This phase 3 trial will investigate the effectiveness of pembrolizumab (Keytruda) in combination with pre-surgery chemotherapy and after-surgery hormonal therapy in patients with high-risk early-stage breast cancer (BC). The main outcomes to be measured will be the response to treatment and survival. The details...
Read MoreLooking for patients with breast cancer to trial a new medication
In a nutshell This phase 3 trial will investigate the effectiveness and safety of ribociclib (Kisquali) in breast cancer (BC). The main outcome will be the rate of survival without disease. The details Breast cancer (BC) is a common form of cancer. Cancers, including BC, can be categorized depending on certain proteins. Some BCs...
Read MoreSearching for patients with early stage breast cancer to trial a new radiation treatment plan
In a nutshell The trial aims to investigate a new way of delivering radiation therapy in women with early-stage breast cancer. This will involve low doses of radiation therapy being aimed at the part of the breast where the tumor is or was. The main outcomes that will be measured are side effects and recurrence rate. This trial is recruiting in Missouri,...
Read More
